News
Seattle Genetics, Inc.: Double-Digit Revenue Growth, but the Best Is Yet to Come
Sales of Seattle Genetics's (NASDAQ: SGEN) Adcetris in the U.S. and Canada jumped 13% year over year in the third quarter, but it's still a relatively small seller for a cancer drug, especially....
Can Juno Therapeutics Outmaneuver Its CAR-T Competitors?
Novartis(NYSE: NVS) filed for Food and Drug Administration (FDA) approval of its chimeric antigen receptor T-cell therapy (CAR-T), Kymriah, in late-stage diffuse large B-cell lymphoma (DLBCL)....
If I Could Buy Only 1 Stock, This Would Be It
What are the top three things you like in a stock? For me, the answer is pretty easy: I like growth most of all. Everyone wants their stocks to appreciate in value.Second, I like dividends. The....
Ionis Down Big on Analyst Miss
This week, Biogen (NASDAQ: BIIB) reported earnings, and Ionis Pharmaceuticals' (NASDAQ: IONS) stock sold off significantly on the news that its drug Spinraza, which Biogen helps commercialize,....
Why Geron Corporation Stock Is Jumping Today
Shares of the clinical-stage biotech Geron Corporation (NASDAQ: GERN) rose by as much as 13.5% in early morning trading today, thanks to a Fast Track designation from the U.S. Food and Drug....
Pfizer Inc. Q3 Earnings: The Most Important Things to Know
Pfizer's (NYSE: PFE) overall story so far in 2017 has been a mediocre one. The big pharma company's stock is up year to date, but barely half as much as the S&P 500 index. Although Pfizer....
Better Buy: Intuitive Surgical, Inc. vs. Johnson & Johnson
With multiple catalysts likely to fuel its growth, the healthcare sector is fertile ground from which investors can reap sizable profits -- if you know where to look.To help you in this regard,....
Why TransEnterix Stock Is Rebounding Today
TransEnterix (NYSEMKT: TRX), a small-cap robotic-surgery company, is on the rebound today with its shares up by 21.41% on heavy volume, as of 11:05 a.m. EDT.Prior to today's double-digit move,....
2 Top Pharma Stocks on Sale This Week
Like most investors, I love a good bargain. So when the top pharma stocks Celgene Corporation (NASDAQ: CELG) and GlaxoSmithKline plc (NYSE: GSK) both crashed last week, it definitely caught my....
The 3 Best Diabetes Stocks to Buy in 2018
Diabetes is a chronic condition that occurs when the body loses its ability to properly metabolize sugar. Without treatment, people with diabetes end up with too much sugar flowing through their....
How to Invest in Healthcare
Ten thousand Americans will turn 65 years old every day from now through 2029. As those Americans age, they will transform our country's healthcare system -- to the tune of a 5.8% annual increase....
5 Things You Need to Know From Gilead Sciences' Q3 Update
You could probably fit the number of people surprised by Gilead Sciences' (NASDAQ: GILD) third-quarter results inside a phone booth -- if you could even find one. Hepatitis C virus (HCV) drug....
A Me-Too Push By Biopharma Is Crowding the Psoriasis Market
A wave of R&D is leading to next-generation psoriasis drugs that work better than ever. That's great news for patients desperate for new treatment options, but it's bad news for biopharma....
3 Bright Spots in Merck's Q3 Results
You only had to look at Merck's (NYSE: MRK) stock movement to know that the big drugmaker's third-quarter results weren't too great. Merck's share price dropped after the company reported a 2%....
3 High-Yield Dividend Aristocrat Stocks
If dividend stocks were like golf, there would be an elite group of stocks with green jackets like golfing greats who win the Masters tournament get to wear. This group of winners is called the....
Vertex Pharmaceuticals Incorporated: One Eye on Earnings, One on the Pipeline
Vertex Pharmaceuticals (NASDAQ: VRTX) reported solid third-quarter earnings, with sales of its cystic fibrosis drugs up 34% year over year. Nevertheless, investors rightfully have one eye on the....
There's a Lot to Like in AbbVie's Q3 Update
AbbVie (NYSE: ABBV) has set a pattern in recent quarters of meeting or barely exceeding consensus analysts' earnings estimates. It's not that the big biotech hasn't performed well; rather,....
Quintiles IMS Holdings Is Firing on All Cylinders
Quintiles IMS Holdings (NYSE: Q), a service and information provider for the healthcare and life sciences industries, reported its third-quarter results on Thursday, Oct. 26. The company's results....
3 Key Things to Watch in Pfizer's Q3 Results
There wasn't much to get excited about the last time Pfizer (NYSE: PFE) reported its quarterly results. While the big pharma company beat analysts' consensus earnings estimate, it also posted a 2%....
Gilead Sciences Inc. Still Singing the HCV Blues in the 3rd Quarter
Surprisingly strong hepatitis C virus (HCV) sales helped Gilead Sciences (NASDAQ: GILD) enjoy better-than-expected results when the big biotech provided its second-quarter update in July. But that....
Should You Be Worried After Bristol-Myers Squibb's Q3 Results?
It's been an up-and-down kind of year for Bristol-Myers Squibb (NYSE: BMY). Early in 2017, investors were concerned after the company opted not to pursue accelerated approval for a combination of....
3 Dividend Stocks Perfect for Retirement
Retirement is a time to shift one's investment portfolio to a more defensive posture. If this can be done while generating income via dividend payouts, so much the better. We asked three of our....
Here's Why Idera Pharmaceuticals Plunged as Much as 35% Today
Shares of pre-revenue biopharma Idera Pharmaceuticals (NASDAQ: IDRA) sank as much as 35% this morning after the company announced the pricing of a major public stock offering. The company will....
5 Things You'll Want to Watch With AbbVie's Q3 Results
If 2017 ended right now, it would go down as AbbVie's (NYSE: ABBV) best ever. The biotech stock's price has risen a little more than the 50% gains AbbVie made during its first year as a....
What's Behind Amgen's Q3 Revenue Decline
When Amgen (NASDAQ: AMGN) announced its second-quarter results in July, the anemic revenue growth was overshadowed by the company's solid earnings increase and its improved full-year guidance. CEO....